TKI Discontinuation Safe in CML, Improved PROs

(MedPage Today) -- As many as 60% of patients with chronic myeloid leukemia (CML) and sustained deep molecular response being treated with long-term tyrosine kinase inhibition remained in treatment-free remission (TFR) after treatment discontinuation...